An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma

Trial Profile

An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs LTX 315 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Tumour infiltrating lymphocytes
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Lytix Biopharma
  • Most Recent Events

    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top